Compare MSGY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGY | MAIA |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 44.9M |
| IPO Year | 2025 | 2022 |
| Metric | MSGY | MAIA |
|---|---|---|
| Price | $2.70 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 650.6K | ★ 1.0M |
| Earning Date | 12-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $23,318,482.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.82 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $0.83 | $0.87 |
| 52 Week High | $22.20 | $2.74 |
| Indicator | MSGY | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.09 |
| Support Level | N/A | $1.13 |
| Resistance Level | N/A | $1.75 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 47.58 |
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.